HC Wainwright & Co. Initiates Coverage On Lexicon Pharmaceuticals with Buy Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy rating and a price target of $10.
June 17, 2024 | 10:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Lexicon Pharmaceuticals with a Buy rating and a price target of $10.
The initiation of coverage with a Buy rating and a price target of $10 by HC Wainwright & Co. is likely to positively impact the stock price of Lexicon Pharmaceuticals in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100